Company Profile

NATCO PHARMA LTD.

NSE : NATCOPHARMBSE : 524816ISIN CODE : INE987B01026Industry : Pharmaceuticals & DrugsHouse : Natco
BSE921.7513.85 (+1.53 % )
PREV CLOSE (Rs.) 907.90
OPEN PRICE (Rs.) 912.00
BID PRICE (QTY) 0.00 (0 )
OFFER PRICE (QTY) 0.00 (0 )
VOLUME 31175
TODAY'S LOW / HIGH (Rs.)888.10 932.50
52 WK LOW / HIGH (Rs.)556.5 995.05
NSE921.95 13.8 (+1.52 % )
PREV CLOSE(Rs.) 908.15
OPEN PRICE (Rs.) 909.00
BID PRICE (QTY) 0.00 (0 )
OFFER PRICE (QTY) 921.95 (92 )
VOLUME 629673
TODAY'S LOW / HIGH(Rs.) 886.50 932.90
52 WK LOW / HIGH (Rs.)555.1 996

Smart Quotes

1D 1M 3M 1Y 3Y 5Y
STOCK SUMMARY
Trade Value (Rs. in Lacs) 0.00
Dividend Yield(%) 0.73
TTM EPS (Rs.) 19.38
P/E Ratio 47.57
Book Value (Rs.) 221.95
Face Value (Rs.) 2
MCap (Rs. in Mn) 168069.89
Price/Earning (TTM) 35.87
Price/Sales (TTM) 9.54
Price/Book (MRQ) 4.15
PAT Margin (%) 25.13
ROCE (%) 14.85
Incorporation Year : 1981

Management Info :

V C Nannapaneni - Chairman V C Nannapaneni - Managing Director

Registered Office :

Address : Natco House,Road No 2,Banjara Hills,
Hyderabad,
Telangana-500003

Phone : 040-23547532

Registrar's Details : Venture Capital & Corporate Investments Ltd
12-10-167,,MIG- 167,,Bharat Nagar Colony,Hyderabad
Listing : BSE, NSE, MCX
NEWS More
26Mar03-26-2021$Natco Pharma gets nod to acquire 0.96% stake in NATCO Pharma Canada Inc. Natco Pharma gets nod to acq

Natco Pharma has received approval from board to acquire 0.96% stake in NATCO Pharma (Canada) Inc., Post acquisition NATCO Pharma (Canada) Inc., will become wholly owned subsidiary of the company.

Natco Pharma was promoted as a private company to be in the business of research, developing, manufacturing and marketing of pharmaceutical substances and finished dosage forms for Indian and International markets.

Natco Pharma has received approval from board to acquire 0.96%..
16Mar03-16-2021$Natco Pharma rises on foraying into Pheromone based technology for IPM Natco Pharma rises on forayi

Natco Pharma is currently trading at Rs. 827.20, up by 1.30 points or 0.16% from its previous closing of Rs. 825.90 on the BSE.

The scrip opened at Rs. 823.35 and has touched a high and low of Rs. 831.45 and Rs. 818.60 respectively. So far 7331 shares were traded on the counter.

The BSE group 'A' stock of face value Rs. 2 has touched a 52 week high of Rs. 995.05 on 28-Sep-2020 and a 52 week low of Rs. 450.00 on 25-Mar-2020.

Last one week high and low of the scrip stood at Rs. 854.00 and Rs. 808.05 respectively. The current market cap of the company is Rs. 15027.37 crore.

The promoters holding in the company stood at 48.91%, while Institutions and Non-Institutions held 33.21% and 17.88% respectively.

Natco Pharma has forayed into Pheromone based mating disruption technology for Integrated Pest Management (IPM) solution to farmers in India. NATCO through its Crop Health Science (CHS) division is working with ATGC Biotech (ATGC) for the technology. ATGC is a science based innovative technology company concentrating on developing new biosafe molecules and tools to protect diverse crops from insect pests, in collaboration with US based agricultural biotech company ISCA Inc.

During Kharif 2021, NATCO plans to launch its first Green Label Pheromone product for Effective Management of Pink Bollworm (PBW) in cotton crop, under its brand NATMATE PBW. This is the first pheromone-based indigenously manufactured product for mating disruption that received approval from Central Insecticide Board (CIB). With this launch, cotton farmers will have a new and powerful tool to manage PBW.

Natco Pharma was promoted as a private company to be in the business of research, developing, manufacturing and marketing of pharmaceutical substances and finished dosage forms for Indian and International markets.

Natco Pharma is currently trading at Rs. 827.20, up by 1.30 poi..
15Mar03-15-2021$Natco Pharma forays into Pheromone based technology for IPM Natco Pharma forays into Phe

Natco Pharma has forayed into Pheromone based mating disruption technology for Integrated Pest Management (IPM) solution to farmers in India. NATCO through its Crop Health Science (CHS) division is working with ATGC Biotech (ATGC) for the technology. ATGC is a science based innovative technology company concentrating on developing new biosafe molecules and tools to protect diverse crops from insect pests, in collaboration with US based agricultural biotech company ISCA Inc.

During Kharif 2021, NATCO plans to launch its first Green Label Pheromone product for Effective Management of Pink Bollworm (PBW) in cotton crop, under its brand NATMATE PBW. This is the first pheromone-based indigenously manufactured product for mating disruption that received approval from Central Insecticide Board (CIB). With this launch, cotton farmers will have a new and powerful tool to manage PBW.

Natco Pharma was promoted as a private company to be in the business of research, developing, manufacturing and marketing of pharmaceutical substances and finished dosage forms for Indian and International markets.

Natco Pharma has forayed into Pheromone based mating disruption..
15Mar03-15-2021$Natco Pharma informs about press release Natco Pharma informs about p

Natco Pharma has informed that it enclosed press release titled ‘Natco forays into Pheromone based technology for Integrated Pest Management’.

The above information is a part of company’s filings submitted to BSE.

Natco Pharma has informed that it enclosed press release titled..
08Mar03-08-2021$Natco Pharma zooms after its marketing partner gets approval for Everolimus Tablets Natco Pharma zooms after its

Natco Pharma is currently trading at Rs. 875.40, up by 42.65 points or 5.12% from its previous closing of Rs. 832.75 on the BSE.

The scrip opened at Rs. 844.85 and has touched a high and low of Rs. 898.95 and Rs. 839.35 respectively. So far 52344 shares were traded on the counter.

The BSE group 'A' stock of face value Rs. 2 has touched a 52 week high of Rs. 995.05 on 28-Sep-2020 and a 52 week low of Rs. 450.00 on 25-Mar-2020.

Last one week high and low of the scrip stood at Rs. 898.95 and Rs. 796.05 respectively. The current market cap of the company is Rs. 15416.66 crore.

The promoters holding in the company stood at 48.91%, while Institutions and Non-Institutions held 33.21% and 17.88% respectively.

Natco Pharma’s marketing partner -- Breckenridge Pharmaceutical Inc. (BPI), has received final approval for its Abbreviated New Drug Application (ANDA) for Everolimus Tablets (generic for Afinitor) from the U.S. Food and Drug Administration (USFDA).

NATCO's partner BPI plans to launch 2.5 mg, 5 mg and 7.5 mg strengths of the product shortly within the next few weeks. The launch of 10mg strength of the product is subject to confidential terms of a settlement and license agreement entered into with the owner of the Afinitor brand.

The launch date of 10mg strength of the product will be announced at a later date. The above strengths of Everolimus are indicated in the treatment of breast cancer and a few other types of cancers. As per industry sales data, Afinitor and its therapeutic equivalents had generated annual sales of $712 million in USA during the twelve months ending December 2020.

Natco Pharma was promoted as a private company to be in the business of research, developing, manufacturing and marketing of pharmaceutical substances and finished dosage forms for Indian and International markets.

Natco Pharma is currently trading at Rs. 875.40, up by 42.65 po..
Financials More
Rs. in Millions
QTR Dec 20 ANNUAL 20
Net Profit5474745
Gross Profit 707 5831
Operating Profit 10317018
Net Sales 330917902
ROLLING FORWARD P/E (EOD)
EVENT CALENDAR
peer group More
Abbott India (BSE)
 15245.80 (1.32%)
M.Cap ( in Cr)
32396.26
Pfizer (BSE)
 4797.80 (3.88%)
M.Cap ( in Cr)
21948.85
Alkem Laboratories (BSE)
 2832.25 (4.66%)
M.Cap ( in Cr)
33863.80
Sanofi India (BSE)
 8227.25 (1.04%)
M.Cap ( in Cr)
18947.87
Procter&Gamble Healt (BSE)
 6362.40 (1.17%)
M.Cap ( in Cr)
10561.19
Shareholding Pattern More
MUTUAL FUNDS/UTI 9.45 %
PROMOTERS 48.87 %
NON-INSTITUTION 18.65 %
FI/BANKS/INSURANCE 0.19 %
FII 0.01 %
GOVERNMENT 0 %
F & O Quotes